The prevention and treatment of Plasmodium vivax malaria
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In most endemic countries the recommended treatment for P. vivax malaria is a 3 day regimen of chloroquine, or an artemisinin-based combination therapy (ACT), combined with primaquine, usually administered at a total dose of 3.5mg/kg over 14 days [1,7].”
From Plasmodium vivax relapse reservoirs in Ethiopia: microhaplotype sequencing informs recurrent infection origins (2026) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structural absorption by barbule microstructures of super black bird of paradise feathers
McCoy, D. E., Feo, T., Harvey, T. A., & Prum, R. O. (2018) · Nature Communications · doi:10.1038/s41467-017-02088-w · Cited by 7,424
The epidemiology of malaria in a Karen population on the western border of Thailand.
Luxemburger, C., Thwai, K. L., White, N. J., Webster, H. K., Kyle, D. E., Maelankirri, L., Chongsuphajaisiddhi, T., & Nosten, F. (1996) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(96)90102-9 · Cited by 233
Self-citationLacerda, M. V., Mourão, M. P., Alexandre, M. A., Siqueira, A. M., Magalhães, B. M., Martinez-Espinosa, F. E., Santana Filho, F. S., Brasil, P., Ventura, A. M., Tada, M. S., et al. (2012) · Malaria Journal · doi:10.1186/1475-2875-11-12 · Cited by 158
Corbel, V., & N’Guessan, R. (2013) · Anopheles mosquitoes - New insights into malaria vectors · doi:10.5772/56117 · Cited by 136 · cited 3×
“Resistance to organochlorides and pyrethroids has been detected in the Americas, Asia, SE Asia, and the southern Pacific [42,43] where P.”
BackgroundInfluentialNguyen, T.-N., von Seidlein, L., Nguyen, T.-V., Truong, P.-N., Hung, S. D., Pham, H.-T., Nguyen, T.-U., Le, T. D., Dao, V. H., Mukaka, M., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30046-x · Cited by 121 · cited 1×
“These ultrasensitive methods allow detection of the majority of all infected people in endemic areas [27].”
Self-citationMoore, K. A., Simpson, J. A., Wiladphaingern, J., Min, A. M., Pimanpanarak, M., Paw, M. K., Raksuansak, J., Pukrittayakamee, S., Fowkes, F. J. I., White, N. J., et al. (2017) · BMC Medicine · doi:10.1186/s12916-017-0877-6 · Cited by 111 · cited 1×
“vivax malaria in pregnancy is associated with miscarriage and low birth weight [14,15].”
BackgroundSelf-citationWatson, J., Taylor, W. R. J., Bancone, G., Chu, C. S., Jittamala, P., & White, N. J. (2018) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0006440 · Cited by 77
Self-citationBancone, G., Gornsawun, G., Chu, C. S., Porn, P., Pal, S., Bansil, P., Domingo, G. J., & Nosten, F. (2018) · PLOS ONE · doi:10.1371/journal.pone.0196716 · Cited by 65
Self-citation
Research works printed but not linked: 116
- PW Gething, 2011, Modelling the global constraints of temperature on transmission of Plasmodium falciparum and Plasmodium vivax, Parasit Vectors, 4, 92, 10.1186/1756-3305-4-92 · DOI · Paper page
- VA Mironova, 2020, Re-introduction of vivax malaria in a temperate area (Moscow region, Russia): A geographic investigation, Malar J, 19, 1, 10.1186/s12936-020-03187-8 · doi:10.1186/s12936-020-03187-8
- RE Howes, 2016, Global Epidemiology of Plasmodium vivax, Am J Trop Med Hyg, 95, 15, 10.4269/ajtmh.16-0141 · DOI · Paper page
- KH Rieckmann, 1989, Plasmodium vivax resistance to chloroquine?, Lancet, 2, 1183, 10.1016/S0140-6736(89)91792-3 · DOI · Paper page
- M Whitby, 1989, Chloroquine resistant Plasmodium vivax, Lancet, 334, 1395, 10.1016/S0140-6736(89)92002-3 · doi:10.1016/s0140-6736(89)92002-3
- DK Kochar, 2014, A prospective study on adult patients of severe malaria caused by Plasmodium falciparum, Plasmodium vivax and mixed infection from Bikaner, northwest India, J Vector Borne Dis, 51, 200, 10.4103/0972-9062.141760 · DOI
- B Genton, 2008, Plasmodium vivax and Mixed Infections Are Associated with Severe Malaria in Children: A Prospective Cohort Study from Papua New Guinea, PLoS Med, 5, e127, 10.1371/journal.pmed.0050127 · DOI · Paper page
- EFC Lança, 2012, Risk factors and characterization of Plasmodium vivax-associated admissions to pediatric intensive care units in the Brazilian Amazon, PLoS ONE, 7, e35406, 10.1371/journal.pone.0035406 · DOI
- AM Quispe, 2014, Plasmodium vivax hospitalizations in a monoendemic malaria region: Severe vivax malaria?, Am J Trop Med Hyg, 91, 11, 10.4269/ajtmh.12-0610 · DOI
- VB Kute, 2012, Plasmodium vivax malaria-associated acute kidney injury, India, 2010–2011, Emerg Infect Dis, 18, 842, 10.3201/eid1805.111442 · DOI
- World Health Organization, 2014, Severe Malaria, Trop Med Int Health, 19, 7, 10.1111/tmi.12313_2 · DOI · Paper page
- KA Moore, 2017, Mediation of the effect of malaria in pregnancy on stillbirth and neonatal death in an area of low transmission: Observational data analysis, BMC Med, 15, 1, 10.1186/s12916-017-0863-z · DOI · Paper page
- P van den Eede, 2011, Plasmodium vivax sub-patent infections after radical treatment are common in Peruvian patients: results of a 1-year prospective cohort study, PLoS ONE, 6, e16257, 10.1371/journal.pone.0016257 · DOI
- A Daher, 2019, Evaluation of Plasmodium vivax malaria recurrence in Brazil, Malar J, 18, 1, 10.1186/s12936-019-2644-y · DOI
- JR Poespoprodjo, 2009, Vivax malaria: a major cause of morbidity in early infancy, Clin Infect Dis, 48, 1704, 10.1086/599041 · DOI · Paper page
- RJ Commons, 2019, The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis, BMC Med, 17, 151, 10.1186/s12916-019-1386-6 · DOI · Paper page
- MF Boyd, 1934, Observations on naturally induced malaria, South Med J, 27, 155, 10.1097/00007611-193402000-00011 · doi:10.1097/00007611-193402000-00011
- EA Ashley, 2009, Evaluation of three parasite lactate dehydrogenase-based rapid diagnostic tests for the diagnosis of falciparum and vivax malaria, Malar J., 8, 241, 10.1186/1475-2875-8-241 · DOI · Paper page
- J Maltha, 2010, Malaria rapid diagnostic tests: Plasmodium falciparum infections with high parasite densities may generate false positive Plasmodium vivax pLDH lines, Malar J, 9, 1, 10.1186/1475-2875-9-198 · DOI
- J Cunningham, 2019, A review of the WHO malaria rapid diagnostic test product testing programme (2008–2018): Performance, procurement and policy, Malar J, 18
- M Imwong, 2014, High-throughput ultrasensitive molecular techniques for quantifying low-density malaria parasitemias, J Clin Microbiol, 52, 3303, 10.1128/JCM.01057-14 · DOI · Paper page
- NJ White, 2014, Assessment of therapeutic responses to gametocytocidal drugs in Plasmodium falciparum malaria, Malar J, 13
- AR Taylor, 2019, Resolving the cause of recurrent Plasmodium vivax malaria probabilistically, Nat Commun, 10, 5595, 10.1038/s41467-019-13412-x · DOI · Paper page
- M Imwong, 2012, The first Plasmodium vivax relapses of life are usually genetically homologous, J Infect Dis, 205, 680, 10.1093/infdis/jir806 · DOI · Paper page
- M Imwong, 2007, Relapses of Plasmodium vivax Infection Usually Result from Activation of Heterologous Hypnozoites, J Infect Dis, 195, 927, 10.1086/512241 · DOI · Paper page
- T Stewart, 2003, Factors that affect the success and failure of insecticide treated net programs for malaria control in SE Asia and the Western Pacific
- FM Smithuis, 2013, The effect of insecticide-treated bed nets on the incidence and prevalence of malaria in children in an area of unstable seasonal transmission in western Myanmar, Malar J, 12
- N Kwansomboon, 2017, Vector bionomics and malaria transmission along the Thailand-Myanmar border: a baseline entomologic survey, J Vector Biol, 424, 84, 10.1111/jvec.12242 · DOI
- EK Thomsen, 2017, Mosquito behavior change after distribution of bednets results in decreased protection against malaria exposure, J Infect Dis, 215, 790
- MT White, 2018, Mathematical modelling of the impact of expanding levels of malaria control interventions on Plasmodium vivax, Nat Commun, 9, 1, 10.1038/s41467-018-05860-8 · DOI
- K Bayili, 2017, Evaluation of efficacy of Interceptor® G2, a long-lasting insecticide net coated with a mixture of chlorfenapyr and alpha-cypermethrin, against pyrethroid resistant Anopheles gambiae s.l. in Burkina Faso, Malar J, 16, 1, 10.1186/s12936-017-1846-4 · DOI
- C Ngufor, 2017, Which intervention is better for malaria vector control: Insecticide mixture long-lasting insecticidal nets or standard pyrethroid nets combined with indoor residual spraying?, Malar J, 16, 1, 10.1186/s12936-017-1987-5 · DOI · Paper page
- N Protopopoff, 2018, Effectiveness of a long-lasting piperonyl butoxide-treated insecticidal net and indoor residual spray interventions, separately and together, against malaria transmitted by pyrethroid-resistant mosquitoes: a cluster, randomised controlled, two-by-two fact, Lancet, 391, 1577, 10.1016/S0140-6736(18)30427-6 · DOI · Paper page
- H van den Berg, 2012, Global Trends in the Use of Insecticides to Control Vector-Borne Diseases, Environ Health Perspect, 120, 577, 10.1289/ehp.1104340 · DOI · Paper page
- J Mouchet, 1988, Agriculture and Vector Resistance, Int J Trop Insect Sci, 9, 297, 10.1017/S1742758400006238 · DOI · Paper page
- W van Bortel, 2008, The insecticide resistance status of malaria vectors in the Mekong region, Malar J, 7, 1, 10.1186/1475-2875-7-102 · DOI · Paper page
- SL Hoffman, 2015, The March Toward Malaria Vaccines, Am J Prev Med, 49, S319, 10.1016/j.amepre.2015.09.011 · DOI · Paper page
- S Herrera, 2011, Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51, Am J Trop Med Hyg, 84, 12, 10.4269/ajtmh.2011.09-0516 · DOI
- JW Bennett, 2016, Phase 1/2a trial of Plasmodium vivax malaria vaccine candidate VMP001/AS01B in malaria-naive adults: safety, immunogenicity, and efficacy, PLoS Negl Trop Dis, 10, e0004423, 10.1371/journal.pntd.0004423 · doi:10.1371/journal.pntd.0004423
- RO Payne, 2017, Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies, JCI Insight, 2, 1, 10.1172/jci.insight.93683 · DOI
- EM Malkin, 2005, Phase 1 vaccine trial of Pvs25H: A transmission blocking vaccine for Plasmodium vivax malaria, Vaccine, 23, 3131, 10.1016/j.vaccine.2004.12.019 · DOI · Paper page
- Y Wu, 2008, Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs 25 formulated with montanide ISA 51, PLoS ONE, 3
- WH Tham, 2017, Plasmodium vivax vaccine research–we’ve only just begun, Int J Parasitol, 47, 111, 10.1016/j.ijpara.2016.09.006 · DOI
- World Health Organization, 2015, Guidelines for the treatment of malaria
- R Ahmed, 2019, Efficacy and safety of intermittent preventive treatment and intermittent screening and treatment versus single screening and treatment with dihydroartemisinin–piperaquine for the control of malaria in pregnancy in Indonesia: a cluster-randomised, open-la, Lancet Infect Dis, 19, 973, 10.1016/S1473-3099(19)30156-2 · DOI · Paper page
- E Meltzer, 2018, Vivax malaria chemoprophylaxis: the role of atovaquone-proguanil compared to other options, Clin Infect Dis, 66, 1751, 10.1093/cid/cix1077 · doi:10.1093/cid/cix1077
- SA Mikolajczak, 2015, Plasmodium vivax liver stage development and hypnozoite persistence in human liver-chimeric mice, Cell Host Microbe, 17, 526, 10.1016/j.chom.2015.02.011 · DOI · Paper page
- ME Gilder, 2018, Primaquine pharmacokinetics in lactating women and breastfed infant exposures, Clin Infect Dis, 67, 1000, 10.1093/cid/ciy235 · DOI
- JK Baird, 2020, Evaluation of the efficacy and safety of tafenoquine co-administered with dihydroartemisinin-piperaquine for the radical cure (anti-relapse) of Plasmodium vivax malaria in Indonesia—INSPECTOR study, In ASTMH Annual Meeting
- ID Velez, 2020, A randomized, open-label, non-comparative multicenter study to assess the pharmacokinetics, safety, and efficacy of tafenoquine in the treatment of pediatric subjects with Plasmodium vivax malaria (TEACH study), ASTMH Annual Meeting
- JC Haston, 2019, Guidance for using tafenoquine for prevention and antirelapse therapy for malaria—United States, 2019, MMWR Morb Mortal Wkly Rep, 68, 1062, 10.15585/mmwr.mm6846a4 · DOI · Paper page
- NJ White, 1988, Chloroquine Treatment of Severe Malaria in Children, N Engl J Med, 319, 1493, 10.1056/NEJM198812083192301 · doi:10.1056/nejm198812083192301
- J Maguire, 2006, Mefloquine is highly efficacious against chloroquine-resistant Plasmodium vivax malaria and Plasmodium falciparum malaria in Papua, Indonesia, Clin Infect Dis, 2197, 1067, 10.1086/501357 · doi:10.1086/501357
- A Ratcliff, 2007, Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison, Lancet, 369, 757, 10.1016/S0140-6736(07)60160-3 · DOI · Paper page
- A Daher, 2018, Efficacy and safety of artemisinin-based combination therapy and chloroquine with concomitant primaquine to treat Plasmodium vivax malaria in Brazil: An open label randomized clinical trial RBR-79s56s RBR, Malar J, 17, 1, 10.1186/s12936-018-2192-x · doi:10.1186/s12936-018-2192-x
- MJ Grigg, 2016, Efficacy of artesunate-mefloquine for chloroquine-resistant Plasmodium vivax malaria in Malaysia: an open-label, randomized, controlled trial, Clin Infect Dis, 62, 1403, 10.1093/cid/ciw121 · DOI
- AP Phyo, 2011, Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial, Clin Infect Dis, 53, 977, 10.1093/cid/cir631 · DOI · Paper page
- F Smithuis, 2010, Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial, Lancet Infect Dis, 10, 673, 10.1016/S1473-3099(10)70187-0 · DOI · Paper page
- MM Fukuda, 2017, A randomized, double-blind, active-control trial to evaluate the efficacy and safety of a three day course of tafenoquine monotherapy for the treatment of Plasmodium vivax malaria, PLoS ONE, 12, e0187376, 10.1371/journal.pone.0187376 · doi:10.1371/journal.pone.0187376
- S Pukrittayakamee, 1994, Blood Stage Antimalarial Efficacy of Primaquine in Plasmodium vivax Malaria, J Infect Dis, 169, 932, 10.1093/infdis/169.4.932 · DOI
- S Pukrittayakamee, 2008, Effects of different antimalarial drugs on gametocyte carriage in P. vivax malaria, Am J Trop Med Hyg, 79, 378, 10.4269/ajtmh.2008.79.378 · DOI
- JK Baird, 1997, Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels, Am J Trop Med Hyg, 56, 621, 10.4269/ajtmh.1997.56.621 · DOI · Paper page
- AR Hasugian, 2007, Dihydroartemisinin-Piperaquine versus Artesunate-Amodiaquine: Superior Efficacy and Posttreatment Prophylaxis against Multidrug-Resistant Plasmodium falciparum and Plasmodium vivax Malaria, Clin Infect Dis, 44, 1067, 10.1086/512677 · DOI · Paper page
- AP Pasaribu, 2013, A randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine combined with primaquine for radical treatment of vivax malaria in Sumatera, Indonesia, J Infect Dis, 208, 1906, 10.1093/infdis/jit407 · DOI
- K Saravu, 2016, Therapeutic assessment of chloroquine-primaquine combined regimen in adult cohort of Plasmodium vivax malaria from primary care centres in Southwestern India, PLoS ONE, 11, e0157666, 10.1371/journal.pone.0157666 · DOI · Paper page
- CS Chu, 2018, Comparison of the cumulative efficacy and safety of chloroquine, artesunate, and chloroquine-primaquine in Plasmodium vivax malaria, Clin Infect Dis, 67, 1543, 10.1093/cid/ciy319 · DOI · Paper page
- T Shumbej, 2019, Therapeutic efficacy of chloroquine for treatment of Plasmodium vivax malaria cases in Guragae zone southern Central Ethiopia, BMC Infect Dis, 19, 4, 10.1186/s12879-019-4055-7 · DOI · Paper page
- E Mesa-Echeverry, 2019, Chloroquine–primaquine therapeutic efficacy, safety, and plasma levels in patients with uncomplicated Plasmodium vivax malaria in a Colombian Pacific region, Am J Trop Med Hyg, 100, 72, 10.4269/ajtmh.18-0655 · DOI · Paper page
- KR Rijal, 2019, Efficacy of primaquine in preventing short- and long-latency Plasmodium vivax relapses in Nepal, J Infect Dis, 220, 448, 10.1093/infdis/jiz126 · DOI · Paper page
- MR Costa, 2007, Chloroquine-resistant Plasmodium vivax, Brazilian Amazon, Emerg Infect Dis, 13, 7
- A Añez, 2015, Resistance of infection by Plasmodium vivax to chloroquine in Bolivia, Malar J, 14, 261, 10.1186/s12936-015-0774-4 · DOI
- S Xu, 2020, Efficacy of directly-observed chloroquine-primaquine treatment for uncomplicated acute Plasmodium vivax malaria in northeast Myanmar: A prospective open-label efficacy trial, Travel Med Infect Dis, 36, 101499, 10.1016/j.tmaid.2019.101499 · DOI · Paper page
- B Russell, 2008, Determinants of in vitro drug susceptibility testing of Plasmodium vivax, Antimicrob Agents Chemother, 52, 1040, 10.1128/AAC.01334-07 · DOI · Paper page
- M Imwong, 2002, Association of genetic mutations in Plasmodium vivax dhfr with resistance to sulfadoxine-pyrimethamine: geographical and clinical correlates, Antimicrob Agents Chemother, 46, 1161, 10.1128/AAC.46.4.1161-1161.2002 · doi:10.1128/aac.46.4.1161-1161.2002
- DN Hupalo, 2016, Population genomics studies identify signatures of global dispersal and drug resistance in Plasmodium vivax, Nat Genet, 48, 953, 10.1038/ng.3588 · DOI · Paper page
- NJ White, 2011, Determinants of relapse periodicity in Plasmodium vivax malaria, Malar J, 10, 297, 10.1186/1475-2875-10-297 · DOI · Paper page
- J Recht, 2018, Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: divergent policies and practices in malaria endemic countries, PLoS Negl Trop Dis, 12, e0006230, 10.1371/journal.pntd.0006230 · DOI · Paper page
- EC Duarte, 2001, Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria, Am J Trop Med Hyg, 65, 471, 10.4269/ajtmh.2001.65.471 · doi:10.4269/ajtmh.2001.65.471
- RSU da Silva, 2003, Esquemas terapêuticos encurtados para o tratamento de malária por Plasmodium vivax, Rev Soc Bras Med Trop, 36, 235, 10.1590/S0037-86822003000200007 · doi:10.1590/s0037-86822003000200007
- S Negreiros, 2016, Efficacy of chloroquine and primaquine for the treatment of uncomplicated Plasmodium vivax malaria in Cruzeiro do Sul, Brazil, Am J Trop Med Hyg, 95, 1061, 10.4269/ajtmh.16-0075 · DOI · Paper page
- S Ladeia-Andrade, 2019, Monitoring the efficacy of chloroquine-primaquine therapy for uncomplicated Plasmodium vivax malaria in the main transmission hot spot of Brazil, Antimicrob Agents Chemother, 63, e01965, 10.1128/AAC.01965-18 · DOI · Paper page
- J Carmona-Fonseca, 2009, Prevention of Plasmodium vivax malaria recurrence: Efficacy of the standard total dose of primaquine administered over 3 days, Acta Trop, 112, 188, 10.1016/j.actatropica.2009.07.024 · DOI
- JK Baird, 1997, Whole Blood Chloroquine Concentrations with Plasmodium vivax Infection in Irian Jaya, Indonesia, Am J Trop Med Hyg, 56, 618, 10.4269/ajtmh.1997.56.618 · doi:10.4269/ajtmh.1997.56.618
- CS Chu, 2018, Chloroquine versus dihydroartemisinin-piperaquine with standard High-dose primaquine given either for 7 days or 14 days in Plasmodium vivax malaria, Clin Infect Dis, 68, 1311, 10.1093/cid/ciy735 · DOI
- WRJ Taylor, 2019, Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial, Lancet, 394, 929, 10.1016/S0140-6736(19)31285-1 · DOI · Paper page
- J Arnold, 1954, The effect of continuous and intermittent primaquine therapy on the relapse rate of Chesson strain vivax malaria, J Lab Clin Med, 44, 429
- T Leslie, 2008, A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of plasmodium vivax in Northwest Frontier Province, Pakistan, PLoS ONE, 3, e2861, 10.1371/journal.pone.0002861 · DOI
- S Kheng, 2015, Tolerability and safety of weekly primaquine against relapse of Plasmodium vivax in Cambodians with glucose-6-phosphate dehydrogenase deficiency, BMC Med, 13, 203, 10.1186/s12916-015-0441-1 · DOI
- AS Alving, 1955, Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine, J Lab Clin Med, 46, 301
- JW Bennett, 2013, Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria, N Engl J Med, 369, 1380, 10.1056/NEJMc1301936 · DOI · Paper page
- BS Pybus, 2013, The metabolism of primaquine to its active metabolite is dependent on CYP 2D6, Malar J, 12, 212, 10.1186/1475-2875-12-212 · DOI · Paper page
- RE Howes, 2013, Spatial distribution of G6PD deficiency variants across malaria-endemic regions, Malar J, 12, 418, 10.1186/1475-2875-12-418 · DOI · Paper page
- RS Hockwald, 1952, Toxicitiy of primaquine in negroes, JAMA, 149, 1568, 10.1001/jama.1952.72930340027010c · doi:10.1001/jama.1952.72930340027010c
- R Rueangweerayut, 2017, Hemolytic potential of tafenoquine in female volunteers heterozygous for glucose-6-phosphate dehydrogenase (G6PD) deficiency (G6PD Mahidol variant) versus G6PD-normal volunteers, Am J Trop Med Hyg, 97, 702, 10.4269/ajtmh.16-0779 · DOI · Paper page
- E Beutler, 1954, The hemolytic effect of primaquine IV. The relationship of cell age to hemolysis, J Lab Clin Med, 44, 439
- A Minucci, 2012, Glucose-6-phosphate dehydrogenase (G6PD) mutations database: review of the “old” and update of the new mutations, Blood Cells Mol Dis, 48, 154, 10.1016/j.bcmd.2012.01.001 · doi:10.1016/j.bcmd.2012.01.001
- K Thriemer, 2020, The risk of adverse clinical outcomes following treatment of Plasmodium vivax malaria with and without primaquine in Papua, Indonesia, PLoS Negl Trop Dis, 79, 1
- T Leslie, 2010, The impact of phenotypic and genotypic G6PD deficiency on risk of Plasmodium vivax infection: a case-control study amongst Afghan refugees in Pakistan, PLoS Med, 7, e1000283, 10.1371/journal.pmed.1000283 · DOI · Paper page
- GR Awab, 2021, Protective effect of Mediterranean-type glucose-6-phosphate dehydrogenase deficiency against Plasmodium vivax malaria, Elife, 10, e62448, 10.7554/eLife.62448 · DOI
- J Recht, 2014, World Health Organization
- WM Monteiro, 2016, Fatal primaquine-induced hemolysis in a patient with Plasmodium vivax malaria and G6PD A- variant in the Brazilian Amazon, Clin Infect Dis, 62, 1188, 10.1093/cid/ciw039 · DOI · Paper page
- JA Green, 2014, Tafenoquine at therapeutic concentrations does not prolong Fridericia-corrected QT interval in healthy subjects, J Clin Pharmacol, 54, 995, 10.1002/jcph.302 · doi:10.1002/jcph.302
- S Warrasak, 2018, Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure., Int Ophthalmol, 39, 1767, 10.1007/s10792-018-1003-2 · DOI
- J Ackert, 2019, Randomized placebo-controlled trial evaluating the ophthalmic safety of single-dose tafenoquine in healthy volunteers, Drug Saf, 42, 1103, 10.1007/s40264-019-00839-w · DOI
- S Duparc, 2020, Neurological and psychiatric safety of tafenoquine in Plasmodium vivax relapse prevention: a review, Malar J, 19, 1, 10.1186/s12936-020-03184-x · DOI
- A Llanos-Cuentas, 2019, Tafenoquine versus primaquine to prevent relapse of Plasmodium vivax malaria, N Engl J Med, 380, 229, 10.1056/NEJMoa1802537 · DOI · Paper page
- MVG Lacerda, 2019, Single-dose tafenoquine to prevent relapse of Plasmodium vivax malaria, N Engl J Med, 380, 215, 10.1056/NEJMoa1710775 · DOI · Paper page
- NJ White, 2021, Anti-malarial drug effects on parasite dynamics in vivax malaria, Malar J, 20, e161, 10.1186/s12936-021-03700-7 · DOI
- PL St Jean, 2016, Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial, Malar J, 15, 97, 10.1186/s12936-016-1145-5 · DOI
- S Pal, 2018, Evaluation of a novel quantitative test for glucose-6-phosphate dehydrogenase deficiency: bringing quantitative testing for glucose-6-phosphate dehydrogenase deficiency closer to the patient, Am J Trop Med Hyg, 100, 213, 10.4269/ajtmh.18-0612 · DOI · Paper page
- NH Fairley, 1947, Sidelights on malaria in man obtained by subinoculation experiments, Trans R Soc Trop Med Hyg, 40, 621, 10.1016/0035-9203(47)90025-4 · DOI
- JS McCarthy, 2019, Blood schizonticidal activity and safety of tafenoquine when administered as chemoprophylaxis to healthy, nonimmune participants followed by blood stage Plasmodium falciparum challenge: a randomized, double-blind, placebo-controlled Phase 1b study, Clin Infect Dis, 69, 480, 10.1093/cid/ciy939 · doi:10.1093/cid/ciy939
- NJ White, 2002, The assessment of antimalarial drug efficacy, Trends Parasitol, 18, 458, 10.1016/S1471-4922(02)02373-5 · DOI · Paper page
- L von Seidlein, 2019, The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in southeast Asia: A cluster randomised trial, PLoS Med, 16, 1, 10.1371/journal.pmed.1002745 · DOI · Paper page
- MS Hsiang, 2013, Mass drug administration for the control and elimination of Plasmodium vivax malaria: an ecological study from Jiangsu province, China, Malar J, 12, 383, 10.1186/1475-2875-12-383 · DOI
- RM Garfield, 1983, Changes in malaria incidence after mass drug administration in Nicaragua, Lancet, 322, 500, 10.1016/S0140-6736(83)90523-8 · DOI
Cited by
Osborne, A. A., Ruybal-Pesantez, S., Rai, A., Trimarsanto, H., Hoon, K. S., Piera, K., Kleinecke, M., Rumaseb, A., Sutanto, E., Thriemer, K., et al. (2026) · doi:10.64898/2026.11.12.765293
Metadata
- Authors
- Chu, C. S., & White, N. J.
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2021-04-23
- Volume
- 18
- Issue
- 4
- Pages
- e1003561
- ISSN
- 1549-1676
- Cited by
- 88
- References
- 8
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.